An observational study in Inflammatory Disorder of Immune System, Spondylitis, Ankylosing and Arthritis, Rheumatoid, sponsored by Centre Hospitalier Régional d'Orléans. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Centre Hospitalier Régional d'Orléans · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Spondylitis, Ankylosing with a site in France — 6 open to participants now, 7 under way, none of them phase 3. Spondylitis, Ankylosing · France.
Among the 68 studies in Spondylitis, Ankylosing with a site in France, this one is the 20th largest by planned enrollment of the 24 observational ones that give a count, is one of 2 that started in 2025, is one of 25 observational ones, and was the 67th registered.
535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.
Browse Spondylitis, Ankylosing studies →6 of the 68 studies in Spondylitis, Ankylosing with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Fresenius Kabi, France · Sites in France, Guadeloupe, Martinique
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Exactech · Sites in France, United States, Canada and 3 more countries
Ages 21+
University Hospital, Grenoble · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 201 across 216 observational studies indexed under Spondylitis, Ankylosing.
Median enrollment 210 across the 43 interventional studies, 519 across the 24 observational. Of the 50 that completed or were terminated, 24 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 68 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Régional d'Orléans is the lead sponsor of 132 studies on the registry; 32 are open to participants now.
Centre Hospitalier Régional d'Orléans has 1 study filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
2 of the studies in Spondylitis, Ankylosing with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05866614CelltrionA Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps | 2027-03 |
| NCT06842316Centre Hospitalier Régional d'OrléansEffects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases | 2027-04-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 68 studies in Spondylitis, Ankylosing with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Cannabis, in addition to its psychotropic properties, could have anti-inflammatory and immunomodulatory effects. Phytocannabinoids (pCBs) are a group of molecules naturally secreted by the cannabis plant. The major pCBs are cannabidiol (CBD) and Δ9-tetrahydrocannabinol Δ9 (THC). Only THC has psychotropic effects, which CBD does not have. Alongside these two main components, there is a wide variety of other molecules, such as other pCBs and terpenes which could increase the effects on immune system through synergistic interactions between these different compounds ("entourage effect").In vivo, pCBs essentially interfere with the endocannabinoid system, acting on many ubiquitous receptors, present on a significant number of different cell types. Numerous published studies show that pCBs have immunomodulatory and anti-inflammatory properties by acting on several of these receptors, whether through modulation of the immune response of different cell types, effects on cytokine networks, reduction of innate and adaptive responses and/or impact on cell survival or death (autophagy, proliferation/ apoptosis). The Immune-Mediated Inflammatory Diseases (IMIDs) affect 5 to 7% of the general population in Western countries, involve different organs (joints, skin, digestive tract) but share the same inflammatory mechanisms resulting from a dysregulation of the immune response. Our research focuses on the identification of the most effective phytochemical profile of pCBs, allowing an optimal effect on chronic inflammatory pathologies of interest among immune-mediated chronic inflammatory diseases (IMIDs). The pCB-IMIDs project is therefore part of an innovative translational project, around new therapeutic applications of medical cannabis (CannAppIMIDs). In our study, we will include 100 patients with one of IMIDs among Rheumatoid Arthritis, spondylarthritis, psoriatic arthritis, Sjogren disease and systemic lupus, at different stage and with different treatments. After patient's consent we will collect for research purposes an additional 40 ml of blood during a routine care blood test. Mononuclear and polynucleated blood cells will be exposed in vitro to different full-spectrum pCB extracts (full spectrum extract) including a CBD dominant and low THC extract (\<0.2%), 1 dominant THC extract, 1 balanced THC/CBD extract and 1 dominant CBG extract. In this cross-sectional study, our objective will be to assess the biological effects of different pCB compositions on inflammatory profiles (concentrations of pro and anti-inflammatory cytokines and chemokines) and modulations of expression profiles (autophagy, apoptosis, and cannabinoid receptor expression profile).
Background:
The analgesic and anxiolytic properties of cannabis are at the origin of the French experiment on medical cannabis set up in 2020 and led by the ANSM (National Agency for the Safety of Medicines and Health Products) for 5 well-identified pathologies (neuropathic pain, certain forms of pediatric epilepsy, symptoms linked to cancer or anti-cancer treatment, palliative situations and painful spasticity linked to multiple sclerosis). Phytocannabinoids (pCBs) are a group of molecules naturally secreted by the cannabis plant. The main pCBs are cannabidiol (CBD) and Δ9-tetrahydrocannabinol Δ9-THC [1, 2]. Only THC has psychotropic effects, which CBD does not have. Alongside these two main components, there is a wide variety of molecules [cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC) and other terpenes] which are said to have an "entourage effect" by increasing the effects by synergistic interactions between these different compounds [3-7]. CBD of natural origin can be purified without other terpenes corresponding to CBD alone ("CBD isolate") or is combined with terpenes and phytocannabinoids but without THC or any other pCB ("broad spectrum"), or in unpurified form, CBD with terpenes and THC ("full spectrum").
In vivo, pCBs essentially interfere with the endocannabinoid system, acting on numerous receptors present on a large number of different cell types [8]. This means that pCBs can be used to treat a wide range of organs. Numerous published works show that pCBs have immunomodulatory and anti-inflammatory properties by acting on several of these receptors, whether via modulation of the immune response of different cell types, effects on cytokine networks, reduction of innate and adaptive responses [9, 10] and/or impact on cell survival or death (autophagy, proliferation/apoptosis) [8, 9]. Thus, in addition to its neurological effects [10, 11], cannabis possesses anti-inflammatory, pro-autophagic and anti-proliferative properties, which are still imperfectly characterized.
Understanding the mechanisms of action of pCBs, individually or in combination with other molecules present in cannabis, on different therapeutic targets therefore presents an immense challenge in the management of Immune-Mediated Inflammatory Diseases (IMIDs). These IMIDs affect 5 to 7% of the general population in Western countries, and involve different organs (joints, skin, gut) but share the same inflammatory mechanisms, resulting from a deregulation of the immune response.
The pCB-IMIDs project is part of an innovative translational project focusing on new therapeutic applications for medical cannabis (CannAppIMIDs).
Objectives:
The objective of this exploratory project is to evaluate the biological and immunological effects of exposure of blood cells from patients suffering from IMID to different varieties of pCB extracts on:
Methods: Single-center cross-sectional study without prospective follow-up of participants, classified non-interventional study. The study consists, after obtaining consent and verifying the eligibility criteria (with saliva test specific to the study), in taking an additional 40 ml of blood during a planned blood test for research purposes and to collect medical data on patients and their inflammatory pathology.
Mononuclear and polynuclear blood cells from subjects suffering from IMID will be exposed in vitro to different inflammatory inducers used individually and/ or all together (LPS- bacterial Lipopolysaccahride, TLR-4 ligand and/or poly-I:C , TLR-3 ligand and/or PAM3CSK4, TLR1/TLR2 ligand, and/or PHA-P - phytohemagglutin P, polysaccharide and glycoprotein ligand) with and without the concomitant addition of different complete spectrum of pCB extracts (full spectrum) including a dominant CBD extract and low in THC (\<0.2%), 1 dominant THC extract, 1 balanced THC/CBD extract and 1 dominant CBG extract. The same analyzes will be carried out in the presence of a recognized anti-inflammatory (for example hydrocortisone or dexamethasone) which will thus serve as a positive control [12].
All analyses will be carried out at CBM - UPR4301 CNRS. Results will allow us to formulate hypotheses, guide and argue for future clinical research studies evaluating the benefit(s) and tolerance of extracts rich in pCB in taking in therapeutic management of IMIDs.
In this exploratory study, the study population will include subjects suffering from IMID with rheumatological expression: rheumatoid arthritis (RA), Spondyloarthropathies with or without IBD, Psoriatic arthritis (Rpso), systemic lupus erythematosus (SLE), Sjögren's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 patients without, 10 patients under basic treatment (csDMARDs\*) and 10 patients under biotherapy or targeted therapy
Other: 1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)
20 patients with or without IBD, including 10 under biotherapy or targeted therapy
Other: 1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)
10 patients without, 10 patients with basic treatment (csDMARD) and 10 patients under biotherapy or targeted therapy
Other: 1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)
10 patients with connective tissue disease (Systemic lupus erythematosus)
Other: 1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)
10 patients with connective tissue disease (Sjögren's syndrome)
Other: 1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)
Mononuclear and polynuclear peripheral blood cells from subjects suffering from IMID will be exposed in vitro to different inflammatory inducers with and without the concomitant addition of at least 4 different pCB extracts spectrum complete (full spectrum) including a dominant CBD extract and low in THC (\<0.2%), 1 dominant THC extract, 1 balanced THC/CBD extract and 1 dominant CBG extract. The same analyzes will be carried out in the presence of a recognized anti-inflammatory (for example hydrocortisone or dexamethasone) which will thus be used as a positive control.
The primary outcome is to evaluate the biological effect of exposure of blood cells from patients suffering from IMID to different varieties of pCB extracts on the inflammatory profile.
The initial inflammatory profiles of patients will be established by evaluations at the transcriptomic and protein level.
Time frame: One sample at inclusion for all patients
The primary outcome is to evaluate the immunological effect of exposure of blood cells from patients suffering from IMID to different varieties of pCB extracts on the inflammatory profile.
In plasma, the concentrations of cytokines and chemokines associated with inflammation, pro (mainly TNF-α IFN-α, but for instance also IL6, IL8, and IL1-β) and anti-inflammatory (for example IL-10) will be quantified in Multiplexed (34-plex type) or conventional ELISA. The level of expression of the corresponding transcripts, produced by the sorted subpopulations (cellular targets: polymorphonuclear, CD14+ monocyte, CD19+ B lymphocytes, CD4+ T4 lymphocytes and CD8+ T8 lymphocytes) will subsequently be reported by BRB-Seq \[13\] and/or by droplet RT-PCR (RT-ddPCR) assays. This quantification technique is reproducible, requires little starting biological material and is very efficient in detecting small quantities.
Time frame: One sample at inclusion for all patients
Inflammatory and autophagic/apoptotic transcripts, as well as transcripts of the main phytocannabinoid receptors in subpopulations of sorted blood cells.
Quantify ex vivo (by BRB-Seq and/or droplet quantitative RT-PCR (RT-ddPCR)). nflammatory and autophagic/apoptotic transcripts, as well as transcripts of the main phytocannabinoid receptors in subpopulations of sorted blood cells (polymorphonuclear cells, CD14+ monocytes, CD19+ B lymphocytes, CD4+ T and CD8+ T cells and if possible, quantify the evolution, after induction of an inflammatory context, of transcripts.
Time frame: One sample at inclusion for all patients
The main phytocannabinoid receptors in blood cells
Quantify ex vivo (by BRB-Seq and/or droplet quantitative RT-PCR (RT-ddPCR)). the expression profile of phyto and endocannabinoid receptors in the subpopulations will be established. Note that the development of this quantification of the transcripts of certain cytokines and several pCB receptors has already been carried out during previous work in the CBM laboratory (on French blood institution blood donors). Finally, an evaluation of mRNAs associated with apoptosis and autophagy could also be documented. Indeed, autophagy, a crucial biological function for the cell, linked to inflammation \[14, 15\], will also be evaluated, because the combined effects of pCB, pro-apoptotic, pro-autophagic and anti-inflammatory, have already been reported.
Time frame: One sample at inclusion for all patients
The main autophagy genes and apoptosis genes such as caspases
Quantify ex vivo (by BRB-Seq and/or droplet quantitative RT-PCR (RT-ddPCR)). Inflammatory and autophagic/apoptotic transcripts, as well as transcripts of the main phytocannabinoid receptors in subpopulations of sorted blood cells (polymorphonuclear cells, CD14+ monocytes, CD19+ B lymphocytes, CD4+ T and CD8+ T cells, and quantify the evolution, after induction of an inflammatory context, of transcripts.
Time frame: One sample at inclusion for all patients
Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Régional d'Orléans →